TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25173761
Drug: Disodium folinate
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disodium folinate 300 mg/m(2)
Study: 17934184
Drug: Atomoxetine (0.5-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.5-1.5 mg/kg/day)
Study: 17065669
Drug: ALA600 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA600 (600 mg once daily)
Study: 17065669
Drug: ALA1200 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA1200 (1200 mg once daily)
Study: 17065669
Drug: ALA1800 (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA1800 (1800 mg once daily)
Study: 14676592
Drug: Zinc treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treatment (15 mg for ≤12 months, 30 mg for >12 months)
Study: 10072830
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg Bid)
Study: 10072830
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet Bid)
Study: 3511284
Drug: Intravesical bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical bacillus Calmette-Guerin (120 mg in 50 ml saline) weekly for 6 weeks
Study: 23167718
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous oxytocin
Study: 12556776
Drug: Omeprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (80 mg intravenous bolus followed by infusion at 8 mg/hour for 72 hours)
Study: 11524327
Drug: Ketamine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.15 mg/kg IV just after the induction of anesthesia)
Study: 9315993
Drug: Sertindole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (4 mg dose increments up to 24 mg, maintained for 5 days, every other day for group 1)
Study: 9315993
Drug: Sertindole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (4 mg dose increments up to 24 mg, maintained for 5 days, daily for group 2)
Study: 23208074
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg elemental calcium carbonate) plus Vitamin D (400 IU of vitamin D(3))
Study: 18177428
Drug: Axial implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axial implants
Study: 18177428
Drug: Tilted implants
Normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilted implants
Study: 12728080
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/L)
Study: 12728080
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 mg/L zinc)
Study: 11203652
Drug: Implant-supported prostheses
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported prostheses with tooth connection
Study: 11203652
Drug: Freestanding prostheses
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freestanding prostheses supported by implants
Study: 8695090
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg trimethaphan
Study: 8695090
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg trimethaphan
Study: 8695090
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg trimethaphan
Study: 29282098
Drug: Maintaining serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining serum potassium ≥ 3.6 mEq/L (relaxed control)
Study: 29282098
Drug: Maintaining serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining serum potassium ≥ 4.5 mEq/L (tight control)
Study: 19563707
Drug: Morphine 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.02 mg.kg(‐1).h(‐1) combined with ketamine 0.08 mg.kg(‐1).h(‐1) for 50 h (group mk)
Study: 19563707
Drug: Morphine 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.02 mg.kg(‐1).h(‐1) (group m)
Study: 17241184
Drug: Intracoronary enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary enalaprilat (50 micro g)
Study: 15266832
Drug: Arbidol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbidol (200 mg three times daily for 5 days)
Study: 9506732
Drug: Bromocriptine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5-10 mg/day)
Study: 9506732
Drug: Quinagolide (0.075-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide (0.075-0.3 mg/day)
Study: 9506732
Drug: Cabergoline (0.5-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5-1.5 mg/week)
Study: 2254714
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg d-1)
Study: 2254714
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg d-1)
Study: 2254714
Drug: Diclophenac sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclophenac sodium (75 mg d-1)
Study: 2254714
Drug: Second drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second drug (when fever relapsed)
Study: 28104105
Drug: Control (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (low-dose monotherapy)
Study: 25301296
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (30 mg Fe daily as FeSO4-containing syrup for eight weeks starting immediately after malaria treatment)
Study: 25301296
Drug: Delayed iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed iron supplementation (30 mg Fe daily as FeSO4-containing syrup for eight weeks starting two weeks after malaria treatment)
Study: 18051006
Drug: Vertical grooves
Normalized name: Verticalm
DrugBank: Meclizine (DB00737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertical grooves in the buccal and lingual walls (G2)
Study: 12010235
Drug: Propionyl-l-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-l-carnitine (2 g/day for 3 months) plus verapamil (10 mg weekly for 10 weeks)
Study: 12010235
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg/day for 3 months) plus verapamil (10 mg weekly for 10 weeks)
Study: 12010235
Drug: Propionyl-l-carnitine plus
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-l-carnitine plus verapamil
Study: 3310020
Drug: nabumetone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabumetone (1000 mg at bedtime)
Study: 3310020
Drug: naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (250 mg twice daily)
Study: 25257291
Drug: Org 25935
Normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25935 12 mg twice a day
Study: 12407126
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg (triple therapy)
Study: 10630486
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (400 mg twice daily), clarithromycin (500 mg twice daily), and tinidazole (500 mg twice daily) for six days (Group A)
Study: 10630486
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (400 mg twice daily), clarithromycin (500 mg twice daily), and tinidazole (500 mg twice daily) for seven days (Group B)
Study: 6340412
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment for early closure of patent ductus arteriosus in 13 infants at a median age of 18 hours.
Study: 30557916
Drug: Vibegron 50
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 50 mg/day
Study: 30557916
Drug: Vibegron 100
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 100 mg/day
Study: 30557916
Drug: Vibegron 50
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 50 mg/day and 100 mg/day
Study: 23276436
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (100 μg of selenium as selenium-yeast)
Study: 23276436
Drug: Placebo (placebo-yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo-yeast tablet)
Study: 20678675
Drug: Barnidipine 10
Normalized name: barnidipine
DrugBank: Barnidipine (DB09227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine 10 mg plus losartan 50 mg
Study: 20678675
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg monotherapy
Study: 18247017
Drug: Erlotinib in
Normalized name: Product containing erlotinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib in combination with gemcitabine
Study: 12472549
Drug: Twice-daily dithranol
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dithranol in Lassar's paste
Study: 12472549
Drug: Once-daily dithranol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dithranol in Lassar's paste
Study: 345986
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro aggregation tests with protamine sulfate and hemoglobin solutions
Study: 31189520
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (flexible dose adjustments to 3, 7, or 14 mg once daily)
Study: 23571145
Drug: Transdermal amplitude
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal amplitude modulated signal (TAMS)
Study: 19486178
Drug: Sumatriptan 85
Normalized name: sumatriptan 85 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 85 mg/naproxen sodium 500 mg
Study: 11007576
Drug: CHO (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (2 g/kg body wt carbohydrate in a 10% solution)
Study: 11007576
Drug: ExCHO (Ex
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExCHO (Ex followed by ingestion of carbohydrate solution)
Study: 9084462
Drug: Metoclopramide (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.2 mg/kg three times daily during 14 days)
Study: 3961091
Drug: Individual short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual short-term psychotherapy in combination with medical treatment
Study: 25234311
Drug: ADPKD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADPKD patients with eGFR >60 ml·min(‐1)·1.73 m(‐2)
Study: 19011772
Drug: Amino-acid infusion
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino-acid infusion (4 kJ x kg(‐1) x h(‐1))
Study: 12869077
Drug: Infliximab with
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab with concomitant antimetabolite agents
Study: 10586170
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (2 to 4 RDA daily for 2 weeks)
Study: 6840172
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 10 mg with food (3566 kJ)
Study: 6840172
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 10 mg with dihydralazine 25 mg
Study: 6840172
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 10 mg with phenobarbitone 100 mg daily (1 week pretreatment)
Study: 6840172
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 10 mg with prazosin 1 mg
Study: 31161850
Drug: 3.75 mg/0.1
Normalized name: bevacizumab 3.75 mg/0.15 mL INTRAOCULR SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg/0.1 ml CTM gel
Study: 31161850
Drug: 1.88 mg/0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.88 mg/0.1 ml CTM
Study: 26019245
Drug: Calcium (600
Normalized name: calcium carbonate/vitamin D3 250 mg calcium (600 mg)-125 unit ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (600 mg/d) plus cholecalciferol (200 IU/d) supplementation
Study: 25222307
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A(H1N1)pdm09 vaccine (15 µg)
Study: 25222307
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A(H1N1)pdm09 vaccine (30 µg)
Study: 15477371
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 100 mg/d
Study: 15477371
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 50 mg/d
Study: 3280640
Drug: 1.5 million
Normalized name: colistin 1.5 million UNT Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 million units of intravenous streptokinase
Study: 30738244
Drug: CRP ≥10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP ≥10 mg/L
Study: 24048581
Drug: Control (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (traditional therapy)
Study: 25180530
Drug: Home hand-arm
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home hand-arm bimanual intensive therapy (H-HABIT), 90 hours provided by trained caregivers
Study: 23331333
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) treatment for an average of 4.8 months
Study: 23331333
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for an average of 4.4 months
Study: 18242858
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (EXP and GA)
Study: 9751000
Drug: Non-drug events
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug events
Study: 2528862
Drug: Merck vaccine
Normalized name: ZOSTER VACCINE LIVE (OKA/MERCK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merck vaccine
Study: 1865975
Drug: Pasteur vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasteur vaccine
Study: 2528862
Drug: CLB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLB vaccine
Study: 2528862
Drug: Korean vaccine
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean vaccine
Study: 29956648
Drug: New N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New N-acetylcysteine 2% oral solution
Study: 29956648
Drug: Reference N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference N-acetylcysteine 2% oral solution
Study: 30711316
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine
Study: 19369174
Drug: RotaTeq (pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RotaTeq (pentavalent rotavirus vaccine), three oral doses
Study: 11208686
Drug: N:(G)‐monomethyl‐L‐arginine (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: N:(G)‐monomethyl‐L‐arginine (NO synthase inhibitor)
Study: 9409357
Drug: rhIGF‐I (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (0.10 mg/kg/day)
Study: 9409357
Drug: rhIGF‐I (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (0.05 mg/kg/day)
Study: 3653529
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg p.o. 3 times/day for 4 days and 10 mg 1.5 h before investigation
Study: 31797532
Drug: 1-month duration
Normalized name: clonidine hydrochloride 0.1 MG/ML [Duraclon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month duration of dual antiplatelet therapy (DAPT) after elective drug-coated balloon angioplasty
Study: 29325367
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment and health education
Study: 26257511
Drug: HCP1004 (naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCP1004 (naproxen 500 mg and esomeprazole strontium 20 mg)
Study: 26257511
Drug: VIMOVO® (naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIMOVO® (naproxen 500 mg and esomeprazole magnesium 20 mg)
Study: 11099371
Drug: Siberian ginseng
Normalized name: Siberian Ginseng
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siberian ginseng (ES) 1,200 mg/day
Study: 1727915
Drug: Pamidronate disodium
Normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate disodium (APD) 60 mg as a single 24-hour infusion
Study: 1727915
Drug: Etidronate disodium
Normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate disodium (EHDP) 7.5 mg/kg given as a 2-hour infusion daily for 3 days
Study: 29603286
Drug: Lettuce (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lettuce (300 g with 30 mL mayonnaise)
Study: 29603286
Drug: Rhubarb (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb (300 g with 60 mL lactose free cream)
Study: 29603286
Drug: Bread (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread (2 slices with 10 g butter)
Study: 24428461
Drug: Intensive quitline
Normalized name: quinoline yellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive quitline support in combination with tailored supplementary materials
Study: 18018469
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg daily for six months
Study: 8102430
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 2.7 g daily for 6 weeks
Study: 3770031
Drug: Carminomycin (CMM)
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carminomycin (CMM) 20 mg/m2
Study: 3770031
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 75 mg/m2
Study: 29978276
Drug: Electrical Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Stimulation (ES) guidance for BoNT A injection
Study: 29978276
Drug: Ultrasonography (USG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonography (USG) guidance for BoNT A injection
Study: 25701140
Drug: Pharmacological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological intervention (250 μg of recombinant hCG)
Study: 25701140
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (150 IU/day of recombinant follicle-stimulating hormone starting on menstrual cycle day 3)
Study: 23877348
Drug: lactulose plus
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: lactulose plus rifaximin 1,200 mg/day
Study: 18184031
Drug: Telephone self-report
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone self-report of medication use
Study: 8828546
Drug: NSAID drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID drug challenge
Study: 29901705
Drug: Rituximab as
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab as first-line treatment
Study: 18242934
Drug: Nursing care
Normalized name: Petrolatum Topical application Ointment [NURSING CARE PROTECTIVE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nursing care (self-efficacy promotion and medical treatment of vascular risk factors)
Study: 9121810
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus placebo (M + P)
Study: 9121810
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus nimodipine (M + N)
Study: 9121810
Drug: Morphine only
Normalized name: Morphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine only (M)
Study: 9121810
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg every 8 h)
Study: 30372482
Drug: SER (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER (50 to 200 mg/d) + GCBT
Study: 23955660
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (PC) intervention
Study: 22945620
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) for depression, 16 to 20 sessions
Study: 16512088
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg of red vine leaf extract AS 195 twice daily (360 mg in total) for six weeks
Study: 12780674
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (blood concentration 5-10 ng/mL) with MMF and low-dose corticosteroid (stopped after 5 months) and induction with daclizumab
Study: 12780674
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus (blood concentration 10-15 ng/mL) with MMF and standard dose corticosteroid
Study: 10692620
Drug: dextropropoxyphene napsylate
Normalized name: Dextropropoxyphene napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextropropoxyphene napsylate 100 mg
Study: 8223138
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dropropizine
Study: 8223138
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg levodropropizine
Study: 8223138
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg dropropizine
Study: 4036849
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 supplementation (15,000 IU weekly)
Study: 25872943
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) applied to the study group, once a week for the entire period of hospitalization.